"Linezolid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract.
| Descriptor ID |
D000069349
|
| MeSH Number(s) |
D02.065.064.463 D02.241.081.018.110.525 D03.383.129.462.600.550
|
| Concept/Terms |
Linezolid- Linezolid
- N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
- Linezolide
U 100766- U 100766
- 100766, U
- PNU-100766
- PNU 100766
- PNU100766
- U-100766
- U100766
|
Below are MeSH descriptors whose meaning is more general than "Linezolid".
Below are MeSH descriptors whose meaning is more specific than "Linezolid".
This graph shows the total number of publications written about "Linezolid" by people in this website by year, and whether "Linezolid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 6 | 6 |
| 2005 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Linezolid" by people in Profiles.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response. Clin Microbiol Infect. 2024 Sep; 30(9):1207-1208.
-
Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland. Respiration. 2024; 103(9):593-600.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Sep; 30(9):1197.e1-1197.e4.
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
Detection of Genes Encoding Microbial Surface Component Recognizing Adhesive Matrix Molecules in Methicillin-Resistant Staphylococcus aureus Isolated from Pyoderma Patients. Genes (Basel). 2023 03 24; 14(4).
-
Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2023 01 12; 388(2):190.
-
New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents. J Pediatric Infect Dis Soc. 2022 Oct 31; 11(Supplement_3):S101-S109.
-
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2021 09 15; 204(6):713-722.
-
Changes in treatment for multidrug-resistant tuberculosis according to national income. Eur Respir J. 2020 11; 56(5).
-
Linezolid as a treatment option for cutaneous non-tuberculous mycobacterial infections. Dermatol Online J. 2020 Sep 15; 26(9).